Author Archives: Scalper1

Nvidia Conference: Virtual Reality, Smart Cars, Bartender Robots

Robot bartenders, a drone racetrack and liquid nitrogen-concocted food? Silicon Valley geeks know how to get down — and that’s just after-hours. Next week, graphics-chipmaker Nvidia ( NVDA ) is slated to host its annual GPU Technology Conference at the San Jose McEnery Conference Center where virtual reality, artificial intelligence and self-driving cars will take center stage. In conjunction, Nvidia will hold its analyst day Tuesday, when CEO Jen-Hsun Huang is scheduled to deliver a keynote talk. RBC Capital analyst Mitch Steves expects Nvidia to offer an update on its Pascal GPU architecture, virtual-reality offerings and automotive efforts. Steves upped his price target to 36 from 32 on Nvidia stock, which he rates a sector perform. “Overall, we are positive on the VR opportunity and believe that growth rates will remain robust,” he wrote in a research report. Virtual reality is getting a big splash this year, and tech names  Apple ( AAPL ), IBM ( IBM ), Alphabet ( GOOGL ) and Tesla Motors ( TSLA ) are on deck to attend the GTC alongside myriad startups like BriSky, a maker of industrial drones, and Lucid, which makes 3D cameras. Under the GTC umbrella, BriSky, Lucid and 10 others will compete Wednesday for $100,000 during the Emerging Companies Summit. Another eight are slated to present their VR tech in an eight-minute elevator pitch for a chance at $15,000. There’s no denying the summit’s success, which helped launch VR headset-maker Oculus and video game-streaming service Gaikai into worldwide recognition. Facebook ( FB ) later acquired Oculus for $2 billion, and Sony ( SNE ) paid $380 million for Gaikai. Mellanox Technology ( MLNX ) and Xilinx ( XLNX ) will present during the OpenPower Summit, Tuesday through Friday. Moore’s Law physics make power a challenge within the industry. Data centers need faster chips, but those chips overheat quicker. Other splashy GTC events include keynotes from IBM Watson Chief Technology Officer Rob High and Toyota Research Institute (under Toyota Motors ( TM )) CEO Gill Pratt on Wednesday and Thursday. Separately, GTC will feature speakers from Nvidia, Twitter ( TWTR ), IBM, Baidu ( BIDU ), Google and Disney ’s ( DIS ) Pixar.

Workday Financial Software Heading For ‘Success’; Stock Gains Again

Building momentum from a week of positive trade, cloud software developer Workday ’s ( WDAY ) stock gained another 1% Friday morning — nearly 8% for the week — after FBR Capital Markets satisfied itself that Workday’s financial software may “achieve the same level of success as (or greater than) its HCM (human capital management) product suite.” In a research note issued Friday, FBR analyst Samad Samana said that he visited Workday’s Pleasanton, Calif., headquarters in Silicon Valley this week and cornered Betsy Bland, vice president of financial management products, and Robynne Sisco, chief accounting officer, who let him “dig deeper into what we have found to be the single most important issue on investors’ minds.” The issue: Will Workday’s financial software do great? “We walked away more confident that the financials business is positioned to have a strong (fiscal 2017) as the product suite has improved significantly, more WDAY reps are now selling financials, a critical mass of live customers is providing positive references for potential customers, and the willingness to adopt cloud-based financials has increased,” Samana said. Investors responded by pushing Workday stock up 2% to 78.34 before easing back to a 1.6% gain above 78 by midday in the  stock market today . On Wednesday, Workday stock broke out of a 12-week, first-stage cup-with-handle base with a 75.60 buy point. Workday competes against no shortage of rivals, including SAP ( SAP ), Salesforce.com ( CRM ) and legacy software developer Oracle ( ORCL ). Salesforce stock was up 1.6% to 74.98 at midday Friday, and Oracle was up fractionally at 40.96. But SAP stock was down 0.8% to 79.74. Samana said he learned that Workday had added more than 45 financial software customers in the fiscal fourth quarter ended Jan. 31, “the most ever in a single quarter.” At 207 financial customers, it’s more than double the base of a year before. For Q4, Workday earnings beat Wall Street views, but its Q1 revenue outlook missed estimates. For fiscal Q1, ending in April, analysts polled by Thomson Reuters expect Workday to lose an adjusted two cents per share minus items, flat with a year earlier, on revenue up 35% to $339 million. Workday went public in October 2012, priced at 28.

Regeneron Soars After Drug Clears Eczema, Sparks Market Size Debate

Big biotech Regeneron Pharmaceuticals ( REGN ) and its big pharma partner Sanofi ( SNY ) said Friday that their potential blockbuster eczema drug candidate sailed through late-stage trials and would be submitted for approval in Q3 of this year. Regeneron shares spiked Friday, headed for their best one-day percentage gain in years. Regeneron’s and Sanofi’s drug dupilumab cleared or nearly cleared the symptoms of atopic dermatitis (eczema) in more than a third of patients, compared with less than 10% of patients in the placebo group, in two clinical trials comprising a total of 1,379 people. Patients on dupilumab in general average around a 70% improvement in the Eczema Area and Severity Index (EASI), whereas the placebo group improved in the 30% to 40% range. “There are no approved systemic therapies in the U.S. for people with moderate-to-severe atopic dermatitis, underscoring the clear unmet need,” Sanofi R&D head Elias Zerhouni said in a statement. “In the U.S., where dupilumab in AD (atopic dermatitis) has been granted Breakthrough Therapy designation by the U.S. FDA, we plan to submit a regulatory application in the third quarter of this year and will work to bring this innovative therapy to patients as quickly as possible.” Evercore ISI analyst Mark Schoenebaum wrote that analysts’ consensus peak annual sales estimate for dupilumab is $4 billion, but there’s quite a bit of variation between individual analysts. “We believe that the current debate for dupilumab is focused on the size of commercial opportunity — it is also in late stage studies for severe asthma (where dupilumab demonstrated high efficacy in phase two in an all-comers population) as well as chronic sinusitis with nasal polyps and eosinophilic esophagitis,” Schoenebaum wrote in an email to clients. “A/D is a relatively new market segment and dupilumab is one of the first therapeutic candidates that could address the high unmet need. … The commercial opportunity in severe asthma may be similarly attractive; however, dupilumab will be facing a more crowded competitive landscape in asthma.” Regeneron shares shot up 13.5% in afternoon trading on the stock market today  to about 409, moving over its 50-day moving average for the first time in 2016. Regeneron stock touched a 17-month low below 349 on March 17. Sanofi stock rose a fraction, above 40.